ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

July 9-13, 2022. London, England, UK.

View by Title View by Number View Themes
Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: PB0561

    Ca2+ and Zn2+ binding to human Protein Z (PZ) induces structural changes that augments its lipid binding

    T. Sengupta1, S. Gayathri2, S. Gupta3

  • Abstract Number: OC 25.2

    Cabozantinib Safety with Different Anticoagulants in Patients With Renal Cell Carcinoma (RCC)

    A. Mesleh Shayeb1, H. Dzimitrowicz2, D. Urman1, N. Dizman3, L. Meza3, A. Sivakumar4, C. Gan5, T. Zhang2, P. Barata6, M. Bilen4, X. Gao7, D. Heng5, S. Pal3, M. Kaymakcalan8, B. McGregor8, T. Choueiri8, R. Mckay1

  • Abstract Number: PB0881

    Calcium-and integrin-binding protein 2 negatively regulates in vivo thrombosis and platelet functions by attenuating S1P production

    M. Naik, K. Golla, N. Shaik, P. Patel, U. Naik

  • Abstract Number: PB1034

    Calcium-dependent monoclonal antibody against Gla-domain of protein S efficiently inhibiting both protein C and TFPI anticoagulant pathways

    B. Dahlback

  • Abstract Number: PB0445

    Calibration of the International Normalized Ratio dedicated to Rivaroxaban according to WHO guidelines

    M. CHEKKAL1, N. YAFOUR2, A. ADDA3, A. BOULENOUAR3, N. ZMOULI3, M. ELHORRI4, A. SAADI OUSLIM5, M. Bennaoum3

  • Abstract Number: PB1097

    Can Low-molecular weight heparin calibrated anti-FXa assays be used to estimate Factor Xa inhibiting Direct Oral Anticoagulant levels?

    W. Pickering1, M. Robinson1, C. Cogswell1, B. Poirier1, C. Solomon2, R. Sarode3

  • Abstract Number: PB0483

    Can Thrombin Generation Assay Predict Bleeding Risk in Patients with Severe Liver Failure?

    A. Navaei1, K. Bruzdoski2, V. Kostousov1, L. Hensch3, S. Hui1, J. Teruya1

  • Abstract Number: PB1142

    Canadian Patient Experience on Switching from Octocog Alfa to Extended Half-Life FVIII Damoctocog Alfa Pegol in Patients with Severe Hemophilia A

    D. Matino1, K. Decker2, E. Iserman1, A. Keepanasseril1, F. Germini1, A. Chan3, L. Walsh1, A. Iorio1

  • Abstract Number: OC 31.3

    Canadian prospective external validation of YEARS and age-adjusted pulmonary embolism testing

    K. de Wit1, F. Al-Haimus2, Y. Hu3, R. Ikesaka4, N. Chan4, Q. Ibrahim4, J. Klyn4, N. Clayton4, F. Germini5

  • Abstract Number: PB0930

    Cancer associated thrombosis on bevacizumab: risk of recurrence and bleeding if bevacizumab is stopped or continued

    M. Mayenga1, N. Falvo2, I. MAHÉ3, A. Jannot4, B. Gazeau5, G. Meyer6, O. Sanchez7, B. Planquette4

  • Abstract Number: VPB0759

    Cancer-associated fibroblasts promote venous thrombosis through C-type lectin-like receptor 2/podoplanin in 3LL lung cancer mouse model

    T. Shirai1, T. Sasaki2, N. Tsukiji2, S. Ohishi2, R. Yokomori2, K. Takano2, K. Suzuki-Inoue3

  • Abstract Number: PB0290

    Caplacizumab for the management of acute immune-mediated thrombotic thrombocytopenic purpura: real world data from the Milan TTP Registry

    P. Agosti1, P. De Leo2, M. Capecchi3, A. Artoni4, I. Mancini5, M. Biganzoli6, B. Ferrari7, S. Gattillo8, S. Trisolini9, E. Rinaldi10, G. Podda11, L. Prezioso12, S. Prassede13, L. Facchini14, D. Caramazza15, G. Tolomelli16, F. Peyvandi17

  • Abstract Number: PB0302

    Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura: Comparative Real-world Multicenter Study

    E. Gavriilaki1, E. Koravou2, S. Besikli2, T. Chatziconstantinou2, E. Nikolousis3, A. Mpanti4, C. Pontikoglou5, C. Kalpadaki5, A. Bitsani6, I. Tassi7, T. Touloumenidou2, M. Papathanasiou2, A. Syrigou2, G. Kaiafa8, E. Kapsali7, E. Papadaki5, A. Anagnostopoulos2, C. Lalayanni2, I. Sakellari2

  • Abstract Number: OC 46.5

    Carbamylation in acute ischemic stroke thrombi impairs t-PA-mediated thrombolysis and increases thrombus frailty

    V. Ollivier1, A. Freiherr Von Seckendorff2, M. Solo Nomenjanahary1, M. BOURRIENNE3, J. Desilles4, M. Mazighi5, B. Ho-Tin-Noé6

  • Abstract Number: OC 13.4

    Cardio-embolic vulnerability predicts hospitalisation in primary care clinically suspected and confirmed COVID-19 patients: a model development and validation study

    F. van Royen1, L. Joosten2, M. van Smeden3, P. Slottje4, F. Rutten3, G. Geersing3, S. van Doorn2

  • Abstract Number: PB1236

    Carrier detection of Glanzmann Thrombasthenia by Flow Cytometry

    R. Dave, T. Geevar, J. Mammen, G. Chellaiya, R. Vijayan, A. Samuel, M. Gowri, S. Nair

  • Abstract Number: PO0056

    Castatrophic Antiphospholipid Syndrome in a Young Woman

    A. Calonge Arribas1, A. Goyache Moreno2, A. Castiella2

  • Abstract Number: PO0067

    Catastrophic Antiphospholipid Syndrome in a 28 years old male: A case report

    C. Poserio, J. Calibuso, H. Warren

  • Abstract Number: PB0293

    Cattle-FRETS71, a Novel Fluorogenic Substrate with Broad Applicability in Characterizing ADAMTS13 Properties and Function.

    J. Barton1, C. Anderson2, F. Miranda2, R. Kelley3, J. Kremer Hovinga4, D. Terrell5, S. Vesely5, J. George6, J. Muia2

  • Abstract Number: OC 32.5

    CD146-positive tumors are associated with venous thromboembolism

    A. Joshkon1, J. Stalin1, W. Traboulsi1, L. Vivancos -Stalin1, M. Nollet1, R. Lacroix2, R. Bachelier1, F. Dignat-George3, A. Bertaud1, A. leroyer1, N. Bardin3, M. Blot-Chabaud1

  • Abstract Number: OC 10.1

    CD36-dependent metabolic rewiring and mitochondrial dysfunction in platelets in response to hyperlipidaemia.

    L. Cheah, M. Hindle, K. Naseem

  • Abstract Number: OC 68.4

    CD39-Bearing Extracellular Vesicles Constrain Platelet Purinergic Signaling-Dependent Pulmonary Thrombosis in Sickle Cell Disease

    T. Brzoska, E. Menchikova, T. Kaminski, S. Tofovic, E. Jackson, M. Gladwin, P. Sundd

  • Abstract Number: OC 57.3

    Cell-based high throughput screening to identify FDA/EMA approved drugs that inhibit the endothelial pro-thrombotic switch during severe COVID19 infection

    D. Jones1, G. Saginc Giannoustas2, C. Peghaire3, D. Pirri2, L. Braga4, E. Schneider5, M. Appiah2, G. Birdsey2, T. McKinnon1, R. Thwaites2, M. Giacca5, A. Randi1

  • Abstract Number: PB0743

    Cell-free DNA is increased in plasma of immunothrombotically dysregulated patients with periprosthetic joint infection in part due to lower DNaseI activity

    R. Herranz1, J. Oto1, M. Fuertes2, E. Plana3, F. Cana4, C. De La Calva2, M. Angulo2, F. Arguelles2, J. Baeza2, I. Baixauli2, F. Baixauli2, J. Amaya2, P. Medina4

  • Abstract Number: PB0262

    Cerebral Sinovenous Thrombosis In Greek Children: A Single Centre Experience

    A. DETTORAKI1, A. Michalopoulou1, M. Gavra2, Z. KAPSIMALI1, S. Thymianou1, S. Vassilopoulou3, A. Kattamis4, C. Kanaka-Gantenbein5, H. PERGANTOU1

  • Abstract Number: PB0266

    Cerebral Venous Sinus Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Risk Factors and Long-Term Outcomes

    L. Johnson-Bishop1, D. Pehlivan1, C. Cohen1, C. Karakas2, S. Bhar1

  • Abstract Number: PB1332

    Cerebral venous thrombosis: clinical, radiological, biological and etiological characteristics of a French Prospective Cohort: Comparison with ISCVT cohort

    A. Triquenot Bagan1, I. Crassard2, L. Drouet3, P. Morange4, V. Wolff5, G. Godenèche6, V. Le Cam Duchez7

  • Abstract Number: PO0031

    Challenges in managing of care in a child with non-severe haemophilia B

    C. Ursu1, M. Serban1, C. Vlad2, A. Traila3, E. Boeriu4, C. Jinca4, E. Boia5, M. Negru5, T. Arghirescu4

  • Abstract Number: PB1128

    Challenges in the management of gynecological bleedings and pregnancies in a woman with severe haemophilia A

    E. Cruz1, M. Coutinho2, F. Leite2, L. Moreira2, N. Pinho2, N. Seidi2, S. Morais3

  • Abstract Number: PB1369

    Challenges of Anticoagulation Management Service and Need of Establishing Pharmacist-Led Anticoagulation Clinic in Tertiary Care Teaching Hospital, Ethiopia: A Qualitative Study

    T. Tadesse

  • Abstract Number: PB0478

    Changes in circulating H3 Histone levels during Extracorporeal Membrane Oxygenation in patients with severe respiratory failure with correlation to haemostatic complications

    A. Doyle1, K. Parmar2, A. Aswani2, K. Breen3, N. Barrett2, A. Retter1, B. Hunt1

  • Abstract Number: OC 61.3

    Changes in fibrinolysis during Extracorporeal Membrane Oxygenation in critically ill adult patients

    A. Doyle1, K. Parmar2, K. Breen3, N. Barrett2, A. Retter1, B. Hunt1

  • Abstract Number: PB0895

    Changes in immature platelet fraction after major trauma: a prospective cohort study

    A. Rossetto1, P. Armstrong2, L. Green3, K. Brohi4, T. Warner2, P. Vulliamy5

  • Abstract Number: PB0152

    Changes in Platelet Functionality and Morphology during Storage of Platelet Concentrates

    A. Khabirova1, L. Fatkhullina2, A. Peshkova3, I. Andrianova1, J. Weisel4, R. Litvinov5

  • Abstract Number: VPB1046

    Changes in Prothrombin time, Activated partial thromboplastin time and Thrombin time Tests of Patients Administered with Different Types of Anticoagulant in Calabar Metropolis, Nigeria

    D. Okpokam1, A. Josephine1, M. Kooffreh-Ada2, E. Iyamah3, P. Zara-Kokpa4, A. Emeribe1

  • Abstract Number: OC 51.2

    Changes in VWF, ADAMTS13, and Complement in Preeclampsia, HELLP syndrome and Other Obstetric Complications: a Single Centre Observational Study.

    L. Neave1, M. Thomas2, R. de Groot3, A. Doyle4, A. David5, K. Maksym6, M. Whitten7, M. Scully8

  • Abstract Number: PB0750

    Changes to platelet quality and function in Waldenstrӧm Macroglobulinaemia

    S. Brysland1, D. Talaulikar2, E. Gardiner3

  • Abstract Number: PB0452

    Changing management of superficial vein thrombosis: a 5 year single site observational study

    R. Gooding1, R. Lavery2, G. Benson2, C. Corrigan2, W. Hamilton2, T. McKernan2, C. Neill2, T. Srikanth2, P. Steele2

  • Abstract Number: PB1337

    Changing Pattern of Venous Thrombosis events in 2021 associated with COVID in a teaching hospital

    H. Rowswell1, T. Nokes2

  • Abstract Number: PB0678

    Changing Recombinant Factor VIII for Plasma-derived FVIII during Immune Tolerance Induction: Results from the Brazilian Immune Tolerance (BrazIT) Study

    S. Rezende1, M. Moreira Dias2, L. de Magalhães3, L. Jardim4, A. De Oliveira5, R. Ribeiro6, V. Franco7, M. Roberti8, F. Callado9, L. Etto10, M. De Cerqueira11, M. Cerqueira12, C. Lorenzato13, I. Pinto14, É. Serafim15, A. Garcia16, T. Anegawa17, D. Neves18, D. Tan19, R. Camelo20

  • Abstract Number: PB1199

    Changing treatment paradigm in second line treatment of adult ITP patients with the availability of TPO agonists: A retrospective study from a tertiary care center in India

    N. GUPTA1, R. Balasubramanian2, Y. Sivaprakasm2, D. Gupta2

  • Abstract Number: PB0796

    Characterisation of 17 Novel Von Willebrand Factor Missense Mutations

    M. Appiah1, A. Shaida2, G. Mobayen2, T. McKinnon3

  • Abstract Number: PB1049

    Characterisation of anti-TFPI Kunitz domain 3 antibodies that selectively inhibit protein S cofactor function.

    A. Petri1, P. Badia Folgado1, D. Jones2, Y. Xu1, I. Salles-Crawley3, J. Ahnström1, J. Crawley1

  • Abstract Number: PB1304

    Characterising Endothelial Colony-Forming Cells in The Context Of HIV: People Living with HIV Have Elevated Endothelial Colony-Forming Cell Frequency

    A. Khawaja1, R. Maughan2, K. Paschalaki2, C. Pericleous2, J. Mason2, M. Nelson3, G. Taylor4, A. Randi1, M. Boffito3, M. Emerson2

  • Abstract Number: PB0824

    Characteristics and Clinical Burden Among Patients With von Willebrand Disease Eligible for Prophylaxis: Results From a Retrospective US Cohort Study

    P. Du1, E. Swallow2, J. Marden2, E. Billmyer2, E. Yim2, S. Sun1

  • Abstract Number: PB1330

    Characteristics and trends of venous thromboembolism – local experience

    D. Kigitovica, V. Gibietis, E. Rusa, S. Strautmane, A. Zaicenko, K. Dzirnieks, J. Birzulis, A. Skride

  • Abstract Number: VPB0128

    Characteristics of Critically Ill COVID-19 Patients with Positive Heparin-Induced Thrombocytopenia Antibody

    T. Nguyen1, T. Tran2, A. Vo1

  • Abstract Number: VPB0978

    Characteristics of the deep vein thrombosis of the upper limb

    R. Ben Salah1, o. Frikha2, F. Mkaouar2, S. Marzouk3, Z. bAHLOUL4

  • Abstract Number: OC 74.3

    Characterization and dissection of new structural variants in FXI deficiency by nanopore sequencing.

    B. de la Morena-Barrio1, Á. Palomo2, A. Rubio3, J. Padilla4, L. Martin5, R. Cifuentes-Riquelme6, C. Bravo-Pérez3, A. Miñano3, V. Vicente6, M. Lozano6, F. vidal7, J. Corral6, M. de la Morena-Barrio6

  • Abstract Number: OC 73.4

    Characterization of a novel anti-GPVI antibody in a humanized GP6 (hGP6KI) mouse model

    S. Navarro1, A. Starke2, H. Brown2, S. Beck3, V. Orth4, J. Heemskerk5, M. Kuijpers6, D. Stegner7, B. Nieswandt8

  • Abstract Number: PB1307

    Characterization of a Novel Genetic Variant in Family with Protein S Deficiency

    V. Votin1, J. Moon1, J. Lim Conley1, J. Kain1, A. Gavini2, I. Tomas3, B. Lewis1, M. Ero1

  • Abstract Number: VPB0206

    Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan

    N. Matsumoto1, H. Abe1, R. Kawasaki1, Y. Tashiro1, M. Noguchi1, S. Harada1, K. Yoneyama2, T. Niino2, T. Soeda1, Y. Yoshimura1

  • Abstract Number: VPB0837

    Characterization of Cellular Pathogenic Mechanism of Type 1 von Willebrand Disease with A1500V mutation

    Y. Chen1, C. Chang2, S. Cheng3, S. Hu1, S. Lai1

  • Abstract Number: PB0530

    Characterization of disseminated intravascular coagulation (DIC) in a murine model of fecal-induced peritonitis

    N. Sharma1, D. Dwivedi2, E. Cani3, M. Lalu4, A. Mendelson5, B. McDonald6, P. Liaw7

  • Abstract Number: VPB0609

    Characterization of TF positive small extracellular vesicles in SARS-CoV-2 infection

    P. Canzano1, M. Brambilla1, R. Frigerio2, M. Cretich2, A. Becchetti3, M. Conti3, M. Camera4

  • Abstract Number: OC 55.2

    Characterization of the Factor VIII and LRP1 Interaction Suggests a Dynamic Binding Mode with Switching of Alternative Multiple Canonical Bivalent and Non-Canonical Electrostatic Contacts

    H. Chun1, J. Kurasawa2, P. Olivares1, E. Marakasova1, S. Shestopal1, G. Hassink3, E. Karnaukhova1, M. Migliorini4, J. Obi5, A. Smith5, P. Wintrode5, P. Durai6, K. Park6, D. Deredge5, D. Strickland4, A. Sarafanov1

  • Abstract Number: PB0370

    Characterization of the human platelet glycome upon storage using tandem mass spectrometry

    M. Lee-Sundlov1, R. Grozovsky2, A. Hanneman3, K. Hoffmeister1

  • Abstract Number: PB0848

    Characterization of the uric acid transporter URAT1 (SLC22A12) in platelets and megakaryocytes

    I. Boukhatem1, J. Bélanger2, O. Ghafoud2, S. Fleury3, M. Welman3, M. Lordkipanidzé3

  • Abstract Number: PB0396

    Characterization of thrombogenic effects of platelet tyrosine phosphatase SHP2 inhibition using the allosteric inhibitor SHP099

    D. Fernández de la Fuente1, L. Hermida-Nogueira2, J. Huang3, S. Veiras4, M. Kuijpers5, J. Heemskerk6, Á. García2

  • Abstract Number: PB0788

    Chloroacilhidroquinone AR-5820 Reduces the Platelet Activity by Inhibition of Mitochondrial Bioenergetics

    E. Fuentes1, D. Mendez2, F. Urra3, S. Fuentes-Retamal3, C. Palominos3, J. Millas-Vargas4, H. Montecino, I. Palomo2, M. Alarcón2, A. Trostchansky5, R. Araya-Maturana2

  • Abstract Number: OC 48.1

    Choice of Anticoagulation in Patients with Low Risk Antiphospholipid Syndrome

    B. Bakow1, Q. Phung2, D. Rabinovich3, J. Reagan1

  • Abstract Number: PB0856

    Chronic inflammation of the liver and bile ducts contributes to platelet hypoactivity and platelet-leukocyte aggregate formation in Mdr2-/- mice

    H. Englert1, J. Gerwers1, N. Wolska1, J. Krause1, D. Schwinge1, C. Schramm2, T. Renné3

  • Abstract Number: PB1325

    Chronobiology of Acute Deep Vein Thrombosis: A 28 Year Study of Lower Extremity Duplex Ultrasounds

    D. Houghton, D. Vlazny, R. Meverden, P. Daniels, M. Bartlett, G. Hesley, A. Lekah, A. Casanegra, W. Wysokinski

  • Abstract Number: PB0730

    Circulating activated protein C levels are reduced in cancer patients, a novel contribution to tumorigenesis?

    J. Oto1, R. Herranz1, E. Plana2, F. Cana3, J. Amaya4, C. Vera-Donoso5, M. Martínez-Sarmiento5, S. Bonanad6, P. Medina3

  • Abstract Number: PB0160

    Circulating EV and platelet releasate proteomes mirror the hyperactive, pro-inflammatory state of COVID-19 patients and may be adjunctive markers of COVID-19 severity

    P. Szklanna1, L. Weiss2, S. Comer1, L. Boehm1, S. Cullivan1, S. Kelliher1, K. Wynne3, C. Scaife4, F. Ní Áinle5, B. Kevane6, P. Maguire7

  • Abstract Number: VPB0608

    Circulating levels of podoplanin and CLEC-2 in COVID-19: an exploratory study

    I. Borba1, F. Lima2, C. Peachazepi de Moraes3, M. Silva Barbosa2, D. Oliveira2, L. Velloso4, E. Mansur4, J. Annichino-Bizzacchi5, F. Costa6, B. Bombassaro2, A. Palma2, E. de Paula4

  • Abstract Number: VPB0791

    Circulating miRNAs release predicts suboptimal response to aspirin in patients at high cardiovascular risk with and without type 2 diabetes mellitus

    R. Liani1, P. Simeone2, S. Ciotti3, R. Tripaldi1, A. Boccatonda4, D. D'Ardes1, A. Recchiuti5, M. Romano5, f. Cipollone1, F. Santilli6

  • Abstract Number: OC 45.1

    Circulatory microRNA-411-5p as a novel prognostic biomarker for major adverse cardiac events in patients with atrial fibrillation

    S. Nopp1, M. van der Bent2, O. Königsbrügge3, D. Kraemmer1, J. Wojta1, I. Pabinger4, C. Ay4, A. Nossent2

  • Abstract Number: PB0291

    Citrullination of plasma proteins in immune-mediated Thrombotic Thrombocytopenic Purpura and sepsis

    T. Arfman1, P. Kaijen1, G. Nicolaes2, J. Voorberg1

  • Abstract Number: PB0794

    Classification of Japanese patients with aHUS treated with eculizumab by a diagnostic scoring system

    H. Wada1, S. Maruyama2, N. Kato2, H. Teranishi3, M. Matsumoto4

  • Abstract Number: PB0971

    Clinical and echocardiographic variables associated with residual perfusion defects after pulmonary embolism

    Ø. Jervan1, J. Gleditsch2, S. Parker3, D. Rashid2, W. Ghanima4, K. Steine5

  • Abstract Number: VPB0436

    Clinical and etiological features of vena cava thrombosis: 69 cases study

    A. Mabrouk1, I. Naceur2, T. Ben Achour2, M. Jridi2, M. Khanfir2, I. Ben Ghorbel2, M. Lamloum2, F. Saïd2, H. Houman2

  • Abstract Number: VPB0418

    Clinical and immunological features of antiphospholipid syndrome

    A. Baya Chatti1, S. Skhiri2, A. Guiga2, W. Ben Yahia2, A. Atig2, N. Ghannouchi2

  • Abstract Number: PB1205

    Clinical and laboratory characteristics of adults with immune thrombocytopenia in a contemporary cohort in Austria

    C. Ungerböck1, T. Schramm2, D. Mehic3, M. Fillitz4, B. Dixer4, C. Ay5, I. Pabinger5, J. Gebhart2

  • Abstract Number: PB1235

    Clinical and mutational spectrum of inherited thrombocytopenia related to cytoskeleton protein defects.

    S. Morais1, C. Monteiro2, M. Pereira3, A. Gonçalves4, M. Gonçalves5, C. Lau5, R. Santos6, E. Cruz7

  • Abstract Number: OC 43.3

    Clinical and phenotypic presentation of patients with low VWF in the Milan Center

    O. Seidizadeh1, A. Ciavarella2, L. Baronciani3, M.T. Pagliari4, G. Cozzi4, P. Colpani3, S. Siboni5, E. Biguzzi6, F. Peyvandi7

  • Abstract Number: PB0036

    Clinical and serological follow up of VITT patients treated with heparin and alternative anticoagulation

    K. Althaus1, G. Uzun2, B. Luz3, M. Wolf4, H. Henkes5, T. Backchoul6

  • Abstract Number: PB0089

    Clinical assessment of coagulation hemostasis in liver cirrhosis associated with COVID-19

    M. Salokhiddinov1, O. Muminov2, Z. Qurbanova3

  • Abstract Number: OC 39.4

    Clinical characteristics and management of children with severe factor VII deficiency- analysis of a United Kingdom cohort

    T. Biss1, J. Motwani2, J. Grainger3, M. Mathias4, S. Stokley5, A. Kelly6, J. Payne7, J. Alamelu8, S. Green9, E. Chalmers10, N. Bhatnagar11

  • Abstract Number: PB1201

    Clinical Characteristics and Maternal/Neonatal Outcomes in Pregnant Women with Immune Thrombocytopenic Purpura: A Systematic Review

    s. khaliq

  • Abstract Number: PB0950

    Clinical Correlation Between Lupus Anticoagulant (LA) and Thrombosis – Ampang Hospital Experience

    S. Nasution1, T. Kunju2, V. Selvaratnam3, L. Kian Boon4

  • Abstract Number: VPB1231

    Clinical efficacy of rituximab in the treatment of adult immune thrombocytopenia: a single center data analysis

    M. Yang1, Z. Zeping2

  • Abstract Number: PB0985

    Clinical experience in factor Xa inhibitors´ reversal with prothrombin complex concentrate in emergency settings

    J. Cerezo Martín1, G. Mendez2, I. Romon2, B. González-Mesones2, M. gonzalez2, M. Pérez2, S. Fernández-Luis2, E. Ocio2

  • Abstract Number: VPB0946

    Clinical Impact of Thromboprophylaxis in Pancreatic Cancer Patients: data from ACT4CAT study

    N. Tsoukalas, A. Christopoulou, E. Timotheadou, I. Athanasiadis, A. Koumarianou, S. Peroukidis, G. Samelis, A. Psyrri, N. Kapodistrias, A. Nikolakopoulos, C. Andreadis, A. Ardavanis, E. Samantas, C. Papandreou, D. Mavroudis, A. Bokas, V. Barbounis, A. Athanasiadis, P. Papakotoulas, I. Boukovinas

  • Abstract Number: PB0710

    Clinical Manifestations and Bleeding Scores in Inherited Factor VII Deficiency; The first national report from Iran.

    A. Khosravi1, M. Paridar2, M. Karimzadeh3, V. Takhviji4, A. Kordian5, O. Kiani Ghalehsardi6, A. Kalantari7

  • Abstract Number: OC 27.2

    Clinical Outcomes Following Prophylaxis With Octocog Alfa in Patients With Moderate Hemophilia A: 8-Year Interim Read-out of the Real-world AHEAD International Study

    M. Ozelo1, C. Hermans2, K. Khair3, B. Guillet4, R. Guerra5, J. Gu5, L. Tang6, M. Carcao7

  • Abstract Number: PB0684

    Clinical Outcomes in Patients with Hemophilia A in Brazil: 3-years of Follow-up of the AHEAD International Study

    M. Cerqueira1, C. Ferreira2, C. Lorenzato3, L. Mesquita Carvalho4, L. Correa Oliveira5, I. Pinto6, A. Prezotti7, J. Gu8, R. Guerra8, L. Tang9, M. Ozelo10

  • Abstract Number: OC 08.5

    Clinical Prediction Tool to Identify Children at Risk for Pulmonary Embolism

    T. Tiratrakoonseree1, S. Charoenpichitnun2, R. Natesirinilkul3, N. Songthawee4, P. Komvilaisak5, P. Pongpicha6, J. Vaewpanich6, N. Sirachainan7

  • Abstract Number: PB0247

    Clinical report of five young patients (3-26 months of age) with moderate or severe hemophilia A receiving emicizumab

    I. Wieland1, L. Hinze2, K. Lambeck1

  • Abstract Number: PB1317

    Clinical series of patients with non-bacterial thrombotic endocarditis not associated with cancer or lupus anticoagulant/antiphospholipid antibodies.

    A. Casanegra1, P. Patrzalek2, D. Houghton1, R. Kurmann1, W. Kuczmik3, D. Hodge4, A. Azza5, K. Klarich1, W. Wysokinski1

  • Abstract Number: PO0057

    Clinical spectrum of antiphospholipid syndrome in a second level general hospital.

    L. Del Carpio-Orantes1, S. García-Méndez2, J. Sánchez-Díaz3, A. Rosas-Lozano3

  • Abstract Number: PB0662

    Clinical Study of Adenovirus-Associated Viral Vector-Mediated Gene Therapy of Human Factor VIII in Severe and Moderately Severe Hemophilia A

    G. Gonen-Yaacovi1, S. Pipe2, K. Stine3, G. Kenet4, A. von Drygalski5, O. Segurado1

  • Abstract Number: PB1393

    Clinical timing of uterotonic medications, tranexamic acid (TXA), and blood transfusions in postpartum hemorrhage (PPH) management

    G. Lee1, A. Serpas1, C. Bereuter1, J. Chu2, H. Ahmadzia1

  • Abstract Number: PB1076

    Clinical utility of ISTH BAT and Thromboelastography in assessment of patients referred for evaluation of bleeding disorders

    p. kafley1, S. Nair2, R. V3

  • Abstract Number: VPB0963

    Clinico-laboratory Findings in Patients with Hereditary Thrombophilia in the North-Western Region of Russia

    V. Soldatenkov1, O. Soldatenkova2, L. Papayan3, N. Silina2, K. Komissarov2, S. Kapustin1, V. Burakov2, N. Saltykova2, O. Matvienko4, O. Smirnova4

  • Abstract Number: PB0619

    Clot Collapse in Scanning Electron Microscopy (SEM)

    S. Baker1, C. Cai1, Z. de Lange-Loots2, M. Pieters2, M. Guthold1

  • Abstract Number: OC 76.5

    Clot Destabilisation by the Inclusion of Fibrin with Truncations in the αC-region

    H. mcPherson1, C. Duval1, T. Feller2, R. Ajjan1, R. Ariëns3

  • Abstract Number: PB1096

    Clot Time Ratio (CTR) in atrial fibrillation patients on rivaroxaban

    L. Onelöv1, E. Theodorsson2, M. Božič Mijovski3, A. Mavri4

  • Abstract Number: VPB0123

    CLOT WAVEFORM ANALYSIS (CWA) PARAMETERS AS INDICATOR OF CoVID-19 OUTCOME

    E. Vagdatli, G. Variti, A. Chalvantzis, V. Katsikari, K. Bani, M. Issa

  • Abstract Number: PB1336

    Clustering of coagulation factors in acute venous thromboembolism identifies clusters of thromboinflammatory and endothelial activation markers as independent predictors of recurrence and mortality.

    A. Pallares Robles1, V. ten Cate2, A. Schulz3, J. Prochaska2, T. Koeck4, S. Heitmeier5, R. Ewert6, M. Halank7, C. Espinola-Klein8, K. Lackner9, T. Münzel10, H. ten Cate11, A. ten Cate-Hoek12, S. Konstantinides13, P. Wild2

  • Abstract Number: OC 76.4

    CM-352 reduces rivaroxaban-associated ICH by mechanisms dependent on MMP-10 and fibrinolysis inhibition

    M. Navarro-Oviedo1, J. Marta-Enguita1, C. Roncal2, J. Rodriguez2, B. Zandio3, R. Lecumberri4, F. Machado1, J. Oyarzabal1, A. Pineda-Lucena1, J. Páramo4, R. Muñoz3, J. Orbe5

  • Abstract Number: PB0957

    Co-inheritance of protein C deficiency and homozygous factor V Leiden mutation: 10-year follow-up on a case with severe presentation.

    A. Sarmento1, C. Almeida1, M. Mendes2, L. Borges2

  • Abstract Number: PB1058

    Coag-Lysis assay, an automated and standardized combined turbidity plasma clot formation and lysis assay

    S. Fontaine1, O. Mathieu1, C. Vauthier1, M. Bourdin2, F. Depasse3, G. Contant1

  • Abstract Number: PB1109

    Coaguchek® Pro II performance evaluation to assess direct oral anticoagulants action. The DOAC-Check study.

    C. Legnani1, M. Cini1, S. Testa2, A. Tosetto3, C. Dellanoce4, S. Bellesso3, G. Carli3, I. Nichele3, L. Lissandrini3, S. Zorzi1, E. Antonucci1, G. Palareti1

  • Abstract Number: VPB0208

    Coagulant potential of emicizumab in child hemophilia A patients

    M. Takeyama1, N. Matsumoto2, H. Abe2, S. Harada2, K. Ogiwara3, S. Furukawa3, T. Soeda2, K. Nogami1

  • Abstract Number: PB1042

    Coagulation activation in newly diagnosed AML is regulated by the heme enzyme myeloperoxidase.

    C. Rolling1, H. Quick2, A. Beitzen-Heineke1, S. Janjetovic3, J. Mäder1, C. Lehr1, C. Bokemeyer1, M. Haddad4, T. Renné4, W. Fiedler1, L. Beckmann5, F. Klingler1, F. Langer1

  • Abstract Number: PB0063

    Coagulation Disorders in Pediatric Patients Hospitalized due to SARS-CoV-2 Infection

    A. DETTORAKI1, A. Michalopoulou1, S. Thymianou1, L. Ioannidou2, S. SASLIS1, M. MAZARAKIS1, I. STAMATI1, Z. KAPSIMALI1, H. PERGANTOU1

  • Abstract Number: OC 28.3

    Coagulation factor XII induces persistent uPAR-integrin β1 signaling promoting DNA damage and senescence in diabetic kidneys

    A. Elwakiel1, K. Shahzad1, I. Gadi1, R. Rana1, D. Gupta1, J. Manoharan1, S. Kohli1, T. Renné2, B. Isermann1

  • Abstract Number: OC 28.5

    Coagulation FXI regulates endothelial cell barrier function by inducing VE-cadherin proteolysis in an ADAM10-dependent manner

    C. Puy1, K. Jordan1, N. Nguyen2, C. Lorentz3, E. Tucker3, D. Gailani4, O. McCarty5

  • Abstract Number: PB0744

    Coagulation markers improve the diagnosis of periprosthetic joint infection: involvement of immunothrombosis

    J. Oto1, R. Herranz1, A. Fernández-Pardo2, M. Fuertes3, E. Plana4, A. Cañada5, F. Cana2, C. De La Calva3, M. Angulo3, F. Arguelles3, J. Baeza3, I. Baixauli3, F. Baixauli3, J. Amaya3, P. Medina2

  • Abstract Number: PB0591

    Coagulation parameters predict COVID-19-related thrombosis in a neural network with a positive predictive value of 98%

    R. de Laat-Kremers1, R. de Jongh2, M. Ninivaggi3, A. Fiolet4, R. Fijnheer4, J. Remijn5, B. de Laat6

  • Abstract Number: VPB0614

    Coagulopathy associated with COVID-19 (CAC)

    h. hadjer1, B. Adel2, G. Faiza3, T. Amina4, A. Samia3

  • Abstract Number: PB0236

    Coinheritance of Combined Factor V and Factor VII Deficiency is Associated With a Mild Bleeding Phenotype in Patient With Non-Transfusion Dependent Thalassemia

    O. Alshareef1, B. Allahyani2, E. Alnasser2

  • Abstract Number: PB0212

    Collaboration between the World Federation of Hemophilia and National Registries for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy

    M. Naccache1, B. Konkle2, D. Coffin1, C. Clark3, L. George4, A. Iorio5, W. Miesbach6, D. Noone7, F. Peyvandi8, S. Pipe9, M. Recht10, M. Skinner11, L. Valentino12, J. Mahlangu13, G. Pierce1, F. Leebeek14

  • Abstract Number: VPB0648

    Combination Thrombolytic Therapy Using Electrohydraulic Radial and Focused Shock Waves in The Animal Model of Embolic Common Carotid Artery Occlusion

    H. Mehrad

  • Abstract Number: PB0564

    Combined Molecular Dynamics and Docking Studies on Direct Oral Anticoagulant Binding to Factor Xa Variants

    D. Veizaj1, D. Poole III2, M. Schreuder3, P. Reitsma4, D. Verhoef4, D. Geerke5, M. Bos6

  • Abstract Number: OC 06.3

    Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: an international retrospective study of outcomes.

    J. GRIS1, C. Bourguignon2, S. Bouvier3, E. Nouvellon4, J. Laurent5, A. Perez-Martin5, E. Mousty6, M. Nikolaeva7, J. Khizroeva8, V. Bitsadze8, A. makatsariya8

  • Abstract Number: VPB1390

    Common risk factors for arterial and venous thrombosis and the recurrence rate in young non-pregnant women

    N. Vereina1, T. Movchan2, V. Chulkov2

  • Abstract Number: PO0014

    Comorbidities of COVID-19 promote Hypofibrinolysis

    R. Gupta

  • Abstract Number: PB1084

    Comparability Of Anti-Xa Assessments Using Alternate Calibration Curves In Patients Receiving Rivaroxaban And Apixaban Therapy

    E. Leitinger, J. Clifford, W. Andrew, S. Chunilal

  • Abstract Number: PB0656

    Comparability of bleeding outcomes by prophylactic FVIII replacement intensity: A post-hoc analysis of a non-interventional study of men with severe hemophilia A

    C. Camp1, C. Hawes1, D. Hinds2, S. Hawley2, D. Reddy2, V. Newman1, E. Goodman2

  • Abstract Number: OC 48.4

    Comparative Effectiveness of Alternative Bridging Therapies for Subtherapeutic INR in Ambulatory Patients with Left Ventricular Assist Devices

    G. Chung1, E. Salem2, E. Sippola3, S. Shore3, L. Baumann Kreuziger2, G. Barnes3

  • Abstract Number: OC 21.5

    Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement estimated through propensity scoring

    H. Liu1, C. Hawes2, C. Hsu1, P. You1, X. Yang1, V. Newman2, T. Robinson1, A. Hatswell3, D. Hinds1

  • Abstract Number: PB0153

    Comparative Pharmacokinetics of Coagulation Factor VIII and IX Products Between Independently Developed and Web-based Population Pharmacokinetic Models

    D. Warad1, J. Reid2, D. Grill3, A. Nageswara Rao1, V. Rodriguez4, A. Ashrani3

  • Abstract Number: PB0068

    Comparative profiles of routine and specialized biomarkers of coagulopathy and endotheliopathy in moderate and severe COVID-19 disease : a prospective observational study

    G. Bousquet1, R. Lacroix2, L. Pahus3, S. Valera3, L. Arnaud3, E. Abdili4, F. Dignat-Georges3, N. Hezard3, L. Papazian5, S. Hraiech6, J. Forel7, P. Morange8, C. Guervilly6, P. Chanez3

  • Abstract Number: PB0549

    Comparative Studies on Clotting and Antiprotease Profile of Heparins of Ovine, Bovine and Porcine Origin

    E. Krupa1, J. Lewis2, A. Farooqui1, O. Iqbal1, W. Jeske1, J. Walenga1, Y. Yao3, J. Fareed4

  • Abstract Number: VPB0567

    Comparative Studies on the Interaction of Heparins from Various Origins with Heparin Cofactor II and Antithrombin

    N. Baig1, A. Kouta1, M. Jaradeh2, D. Hoppensteadt3, W. Jeske1, J. Fareed3

  • Abstract Number: PB1361

    Comparing the proportion of medical and surgical hospital inpatients requiring pharmacological thromboprophylaxis using different risk assessment models: an observational cohort study

    D. Horner1, R. Doonan2, G. Mike3, S. Goodacre3, B. Hunt4, K. de Wit5

  • Abstract Number: PB0929

    Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism

    J. Ong1, E. Leitinger2, S. Chunilal3

  • Abstract Number: VPB0637

    Comparison between Intermittent Bolus versus Continuous Intravenous Infusion of Tranexamic Acid in Hematological Disorders with Thrombocytopenia (BRAVE Trial)

    B. Poojitha1, J. John2, A. Philips2, k. Modak2, P. DS2

  • Abstract Number: PB0701

    Comparison between Self-Administered and Clinician-Administered ISTH Bleeding Assessment Tool in RUNX1 Patient Population

    E. Andrews1, H. Choo-Wosoba2, S. Kalsi3, M. Merguerian4, M. Ring5, J. Davis6, S. Steinberg7, P. Liu8, L. Cunningham8

  • Abstract Number: VPB1120

    Comparison between the DOAC Dipstick test in urine and chromogenic substrate methods in plasma on patients treated with direct oral anticoagulants.

    L. Papageorgiou1, J. Harenberg2, S. Auge3, L. Tredler4, I. Elalamy5, G. Gerotziafas6

  • Abstract Number: PB0322

    Comparison of 2 functional assays (HIMEA and HIPA) for the diagnosis of vaccine-induced immune thrombocytopenia and thrombosis (VITT) : a franco-greek collaborative study

    D. Faille1, A. Kotsiafti2, M. BOURRIENNE3, C. ACHARD4, A. PERRIER-CORNET5, C. Matsouka2, N. Ajzenberg6, V. GKALEA2

  • Abstract Number: PB0785

    Comparison of antiplatelet effects of small phenolic compounds

    M. Hrubša1, S. Parvin2, P. Mladěnka3

  • Abstract Number: PB0911

    Comparison of effectiveness and safety of direct oral anticoagulant versus low molecular weight heparin treatment for venous thromboembolism in patients with active cancer – the OSCAR UK Study

    A. Cohen1, C. Wallenhorst2, C. Becattini3, B. Schaefer4, K. Abdelgawwad4, G. Psaroudakis4, G. Brobert5, C. Coleman6, A. Ekbom7, C. Ay8, A. Lee9, A. Khorana10, M. Carrier11, M. Rivera12, C. Marinez2

  • Abstract Number: PB0624

    Comparison of fibrinogen concentrates to cryoprecipitate in restoring clot integrity and stability against fibrinolytic degradation

    C. Whyte1, A. Rastogi2, E. Ferguson3, M. Donnarumma1, N. Mutch1

  • Abstract Number: PB0055

    Comparison of five different PF4 dependant immunoassays in the diagnosis of Vaccine-induced Thrombotic Thrombocytopenia (VITT)

    T. Geevar1, R. Dave1, D. M2, P. Elizabeth3, D. Daniel4, S. Nair1

  • Abstract Number: PB0260

    Comparison of heparin-induced thrombocytopenia workup and clinical characteristics between pediatric and adult patients

    O. Cohen1, K. Lange2, I. Budnik3, A. Lubetsky1, I. Tamarin1, N. Rosenberg1, G. Kenet4, S. Levy-Mendelovich1

  • Abstract Number: VPB1230

    Comparison of platelet function with different tyrosine kinase inhibitors treatment in chronic myeloid leukemia, in vivo and ex vivo studies

    Y. WU1, C. SHEN2, T. WANG2, C. LIU3

  • Abstract Number: PB1225

    Comparison of platelets function in patients with JAK2V617F or CALR mutated myeloproliferative neoplasms

    A. Guy1, M. Fiore2, K. Helzy3, O. Mansier2, J. Bordet4, E. Riviere5, C. James6

  • Abstract Number: PB0910

    Comparison of standard vs low dose of direct oral anticoagulants for the secondary prophylaxis of venous thromboembolism in patients affected by hematologic malignancies

    A. Serrao1, M. Chavez Orellana2, G. Assanto3, R. Mormile3, E. Baldacci3, C. Santoro4, A. Chistolini2

  • Abstract Number: PB1386

    Comparison of the ETP-based thrombomodulin assay versus the ETP-based APC resistance assay on the ST Genesia system

    L. Morimont1, M. Didembourg2, A. Carlo3, J. Dogné4, J. Douxfils5

  • Abstract Number: PB0918

    Comparison of the Khorana, PROTECHT and ONKOTEV risk assessment models to predict venous thromboembolism in patients with pancreatic cancer

    C. Frere1, L. Gauthier2, C. Canivet3, S. Gourgou2, L. Buscail3, B. Bournet3, D. Farge4

  • Abstract Number: OC 16.4

    COMPASS versus Khorana Risk Assessment Model for Predicting Venous Thromboembolic Events in Patients with Non-Small Cell Lung Cancer on Active Treatment with Chemotherapy and Immunotherapy.

    H. Abdel-Razeq1, B. Sharaf1, R. AlMasri2, R. Bater1, M. Abualsha'r1, O. Salama1, F. Tamimi1, K. Ashouri1, D. Abu Laban1, T. Salameh1, R. Al zughul1, Y. Alhalaseh1

  • Abstract Number: PB0738

    Complement and Haemostasis: Effects of complement inhibitors in a microfluidic bleeding model

    M. Golomingi1, J. Kohler1, C. Lamers2, R. Pouw2, E. Hardy3, D. Ricklin2, W. Lam3, V. Schroeder1

  • Abstract Number: OC 02.1

    Complement Receptors Mediate Binding of Heparin-Induced Thrombocytopenia Immune Complexes to Fc Receptor Bearing Cells

    H. Harris1, S. Khandelwal2, L. Rauova3, D. Cines4, G. Arepally2

  • Abstract Number: PB1043

    Complementary roles of red blood cells and platelets in high-throughput whole-blood thrombin generation

    S. Sun1, J. zou2, J. Konings3, D. Huskens4, J. Wan5, C. Reutelingsperger2, H. ten Cate6, P. de Groot7, B. de Laat8, J. Heemskerk9, M. Roest10

  • Abstract Number: PO0040

    Complex Bleeding Management – Multidisciplinary Approach

    A. Aribandi1, C. Ranjith2, K. Ashok1, R. Gottipati3

  • Abstract Number: PB0264

    Composition of thrombi in pediatric ECMO circuits

    J. Drop1, L. Verhage2, E. Wildschut3, M. De Hoog3, C. van Ommen1, H. van Beusekom2

  • Abstract Number: OC 77.5

    Comprehensive analysis of human glycoprotein Ibα O-glycosylation.

    M. Hollenhorst1, K. Tiemeyer1, K. Mahoney2, K. Aoki3, M. Ishihara3, V. Rangel-Angarita2, C. Bertozzi4, S. Malaker2

  • Abstract Number: PB1171

    Comprehensive Genotype and phenotype characterization in Non-severe Hemophilia A patients on assay discrepancies

    R. Sueldo1, L. Rossetti2, B. Ziegler3, V. Marchione4, P. Radic5, M. Abelleyro6, C. De Brasi7, A. Baques8, M. Arias9

  • Abstract Number: LB 01.2

    Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial

    V. Jiménez Yuste1, P. Angchaisuksiri2, G. Castaman3, K. Cepo4, J. Haaning4, S. Jacobsen4, J. Mahlangu5, T. Matsushita6, K. Nogami7, A. Shapiro8

  • Abstract Number: PB1385

    Concurrent use of Tranexamic acid and hormonal therapy for the management of heavy menstrual bleeding in women

    A. epstein1, O. Turan2, R. Abdul-Kadir3

  • Abstract Number: PB0801

    Conformational dynamics of plasma-derived von Willebrand factor recapitulate isolated A1 domain and autoinhibitory module

    E. Legan1, M. Wilson2, N. Arce1, E. Parker2, P. Lollar2, R. Li1

  • Abstract Number: OC 67.4

    Congenital factor VII deficiency in a large cohort of Portuguese patients — molecular profiling, pathogenicity stratification and genotype-phenotype correlation

    C. Silva Pinto1, I. Rocha2, C. Catarino3, R. Salvado4, M. Costa5, F. Rodrigues6, S. Nobre Fernandes7, C. Geraldes8, T. Fidalgo9

  • Abstract Number: PO0042

    Congenital factor XIII deficiency: a case study

    A. AMIRECHE, H. BROUK

  • Abstract Number: PB1141

    Congenital Haemophilia A with very low titre inhibitor, undetectable by routine methods and presenting with discrepant factor VIII assays post treatment with recombinant FVIII

    D. White, A. Kelly, J. Fox, J. Crowe, S. MacDonald

  • Abstract Number: PB0404

    Connexins are post-translationally modified in activated platelets; potential role of calpain

    A. Elgheznawy1, K. Taylor2, S. Parkes2, J. Gibbins3

  • Abstract Number: OC 40.3

    Consumption of On-demand Factor Concentrates and Bypassing Agents for Management of Breakthrough Bleeds with Fitusiran Prophylaxis in People with Haemophilia A or B: An Analysis of Two Phase 3 Studies

    A. Srivastava1, R. Wu2, C. You3, K. Kavakli4, J. Bartelt-Hofer5, R. Rosim6, Z. Qiu7, V. Cano8, S. Andersson9, S. Pipe10

  • Abstract Number: VPB0328

    Contactless dielectric spectroscopy for detection of platelet-activating antibodies

    N. Khan1, D. Martin2, U. Pliquett2, Y. ZAIKOU2, T. Nacke3, H. Nguyen4

  • Abstract Number: PB0961

    Continued Suspected Direct Oral Anticoagulant Interference on Thrombophilia Testing: Experience of a Reference Laboratory

    E. Wong1, L. Worfolk2, L. Noh3, J. Dlott2

  • Abstract Number: PB0058

    Contribution of biology to the diagnosis and follow-up of VITT: a French multicentre experience.

    C. Pouplard1, C. Vayne2, E. Guery2, N. Ajzenberg3, P. Cauchie4, C. Cordonnier5, E. De Maistre6, M. Donnard7, N. Drillaud8, H. Galinat9, S. Goffard10, I. Gouin11, R. Marlu12, G. Mourey13, F. Mullier14, V. SIGURET15, S. Susen16, M. Tuffigo17, J. Rollin2, Y. Gruel2

  • Abstract Number: VPB1292

    Contribution of isoproterenol in hemostatic alterations in vivo

    Y. Prado1, F. Marchant2, V. Alejandro3, F. Simon3

  • Abstract Number: OC 13.2

    Convalescent Plasma Therapy Does Not Increase the Risk of Thromboembolism in The Treatment of COVID-19: A Systematic Review and Meta-Analysis

    P. Li1, A. Li2, P. Yu3, M. Khalid4, M. Laureano5, M. Crowther6

  • Abstract Number: OC 02.2

    Cooperation between PF4-specific antibodies in heparin-induced thrombocytopenia: a new mechanism potentially contributing to hypercoagulability and thrombosis

    S. Billy1, C. Vayne2, N. Charuel3, L. Coënon3, M. Atsouawe3, C. Pouplard4, Y. Gruel2, J. Rollin2

  • Abstract Number: OC 11.5

    Correction of Coagulopathy in Trauma Haemorrhage – Still Room for Improvement. A Secondary Analysis of the ITACTIC trial

    C. Lindsay1, K. Baksaas-Aasen2, N. Juffermans3, N. Curry4, M. Maegele5, J. Stensballe6, S. Stanworth7, R. Davenport8, P. Næss2, C. Gaarder9, K. Brohi1

  • Abstract Number: VPB0122

    CORRELATION OF CLOT WAVEFORM ANALYSIS (CWA) PARAMETERS WITH THE DAYS OF HOSPITALIZATION OF CoVID-19 PATIENTS

    E. Vagdatli, A. Chalvantzis, M. Issa, G. Variti, V. Katsikari, K. Bani

  • Abstract Number: VPB0170

    Correlation of Factor VIII Activity Measured by One-Stage Clotting and Chromogenic Substrate Assays in a Phase III Study of Emicizumab Prophylaxis for Acquired Hemophilia A (AGEHA)

    K. Yoneyama1, K. Tokuda2, R. Ozaki1, R. Kobayashi1, Y. Oguchi1, A. Kiialainen3, K. Amano4, M. Shima5

  • Abstract Number: VPB0840

    Correlation study between VWF: RCO ristocetin cofactor activity and ISTH-BAT in von Willebrand disease

    R. Messaoudi1, m. amine2

  • Abstract Number: VPB0021

    Correlations between oxidative stress, endothelial injury and coagulation activation in hypertensive patients with chronic kidney disease

    O. Korzh, S. Krasnokutskiy, Y. Fylenko

  • Abstract Number: PB1155

    Cost of factor concentrates in the Brazilian Protocol of Immune Tolerance Induction: preliminary results of the Co$tIT Study

    S. Rezende1, V. Franco2, J. Angela da Silva3, M. Moreira Dias4, A. De Oliveira5, A. Vilela De Oliveira Santos6, R. Ribeiro7, N. Martins Beserra8, C. Lorenzato9, J. Álvares-Teodoro10, R. Camelo11

  • Abstract Number: OC 60.3

    Cost-effectiveness of performing reference ultrasonography in patients with deep vein thrombosis

    C. De Jong1, W. van den Hout2, C. van Dijk3, L. van Dam4, G. Gautam5, W. Ghanima6, J. Gleditsch7, A. von Heijne5, H. Hofstee8, M. Hovens9, M. Huisman10, A. Mairuhu11, M. Nijkeuter12, M. van de Ree13, C. van Rooden14, R. Westerbeek15, J. Westerink16, E. Westerlund5, L. Kroft17, F. Klok1

  • Abstract Number: PB0009

    Could Pharmacoinvasive Strategy Using Streptokinase Be an Alternative to Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction in Resource Poor Settings?

    A. Alex1, M. Gowri2, O. George3

  • Abstract Number: PO0016

    Covid 19 with Hematological presentation and complications that may lead to Stem cell transplant

    F. Alayoubi1, G. Elgohary2

  • Abstract Number: VPB0105

    COVID-19 Coagulopathies – Highlights On 2020-2021 Reported Data

    S. Anil Kumar1, A. Pradhan1, A. Elsebaie1, K. Fainchtein1, A. Noureldin1, Y. Tera1, S. Kazi2, M. Othman1

  • Abstract Number: PB0605

    COVID-19 disease is associated with a hypofibrinolytic state driven by elevated plasminogen activator inhibitor-1 and its cofactor vitronectin

    M. Simpson1, C. Whyte1, G. Morrow2, C. Wallace1, A. Mentzer3, J. Knight3, S. Shapiro4, N. Curry3, C. Bagot5, H. Watson1, J. Cooper6, N. Mutch1

  • Abstract Number: PB0047

    Covid-19 vaccination & Acquired Hemophilia A: the case of a middle aged woman

    M. Daniel1, C. Paris1, A. Hochart1, N. Trillot1, A. Rauch2, B. Wibaut1, E. Jeanpierre3, M. Desvages1, C. Zawadzki1, A. Bauters4, F. Lassalle1, A. Tournoys1, A. Dupont2, L. Terriou1, S. Susen5

  • Abstract Number: PB1133

    COVID-19 vaccination in patients with hemophilia: experience from a single center

    C. Suffritti1, R. Gualtierotti2, E. Scalambrino3, M. Clerici4, A. Lecchi5, C. Novembrino6, E. Biguzzi7, S. Siboni3, S. Arcudi8, A. Ciavarella9, P. Bono10, F. Ceriotti10, F. Peyvandi11

  • Abstract Number: PB0643

    COVID-19-associated hemostasis alterations and outcomes in acute ischemic stroke patients treated with intravenous thrombolysis

    L. Lóczi1, R. Orbán-Kálmándi2, I. Szegedi3, T. Árokszállási4, J. Tóth5, L. Oláh4, L. Csiba6, Z. Bagoly7

  • Abstract Number: PB1414

    COVID-19-associated hemostasis alterations in pregnancy: a prospective, case-control study

    Z. Bagoly1, E. Tóth2, R. Orbán-Kálmándi3, T. Deli4, O. Török4, L. Lóczi5, J. Tóth6, S. Molnár4, Z. Krasznai4

  • Abstract Number: PB0361

    Coxsackievirus B3 infection of CD34+ cells impairs megakaryocyte and platelet production through activation of Toll-like receptors 7 and 8

    M. Schattner1, C. Rodriguez2, N. Charo3, S. Tatti4, R. Gomez5, L. D'Atri6

  • Abstract Number: OC 40.5

    Crimson 1: A Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptocog alfa (activated) for on-demand treatment of bleed events in subjects with hemophilia A or B, with inhibitors

    S. Rangarajan1, S. Desai2, S. Apte3, D. Vaghasiya4, J. Mahlangu5, V. Ramanan6, L. Makhaldiani7, B. Korczowski8, M. Timofeeva9, S. Volkova10, S. Pinnamaraju2, J. Yun2, L. Neuman2, T. Knudsen2, B. Kim2

  • Abstract Number: PB0359

    CRISPR genome editing coupled with optimized biomanufactured human platelets for molecular and functional investigation of platelet biogenesis.

    L. Mallo1, A. Pongerard1, C. GACHET1, Y. KNAPP2, F. Lanza1, C. Strassel1

  • Abstract Number: PB1272

    CRISPR-Based Knockout Red Blood Cells as Tools to Study Red Blood Cell Surface Protein Involvement in Thrombosis

    N. Ouazzani Chahdi1, J. Meijers2, R. van Bruggen3

  • Abstract Number: OC 35.4

    Critical Role for RapGEF2 in PKC-Rap1-Integrin Signaling in Platelets

    D. Paul1, E. Clark2, A. Beale2, W. Bergmeier2

  • Abstract Number: OC 11.1

    Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and strength; results from a sub-study of the FEISTY trial

    G. Morrow1, T. Feller2, Z. McQuilten3, E. Wake4, R. Ariëns5, J. Winearls4, N. Mutch6, M. Laffan7, N. Curry8

  • Abstract Number: PB1003

    CT-001 is a Rapid Clearing Factor VIIa with Enhanced Hemostatic Activity and Safety in Mouse Models of Acute Bleeding

    D. Sim, C. Mallari, J. Teare, M. Bauzon, T. Hermiston

  • Abstract Number: PB0976

    CTPA in pregnant women with suspected pulmonary embolism: effect on neonatal thyroid function

    M. Righini1, A. Elias2, O. Sanchez3, J. Schmidt4, D. Aujesky5, P. Roy6, G. Le Gal7

  • Abstract Number: VPB0350

    Curcumin potentiates an inhibitory effect of cangrelor on platelets

    N. Rukoyatkina1, V. Shpakova2, S. Gambaryan3

  • Abstract Number: PB0955

    Current knowledge on factor V Leiden mutation as a risk factor for recurrent venous thromboembolism: a systematic review and meta-analysis

    D. Eppenberger1, H. Nilius2, B. Anagnostelis1, C. Huber3, M. Nagler4

  • Abstract Number: PB0683

    Current landscape of prophylaxis and tolerisation in patients with Haemophilia A in Australia

    S. PARIKH1, S. P'ng2, S. BROWN3, C. Barnes4, C. TAN5, T. CARTER6, H. Tran7

  • Abstract Number: PB0244

    Current practice of monitoring joint health in children and adolescents with hemophilia in Germany, Austria and Switzerland (GAS)

    M. Reschke1, C. Königs2, N. Marquardt3, M. sigl-Krätzig4, S. Holzhauer5

  • Abstract Number: PB1257

    Custodiol Solution Improves Hemocompatibility of Decellularized Liver Scaffold

    M. Dias1, B. Paranhos1, J. Ferreira2, R. Fonseca3, C. Batista4, R. Martins-Santos1, C. Andrade5, L. Faccioli6, A. Silva7, F. Nogueira8, G. Domont8, R. Goldenberg1

  • Abstract Number: OC 63.5

    Cytokine profile of patients with Acquired Hemophilia A (AHA) in a longitudinal study

    J. Frade-Guanaes1, A. Racanelli1, L. Siqueira1, C. Costa-Lima1, S. Medina1, N. Foschi1, L. De Lima1, A. Francisco1, M. Colella1, S. Montalvão2, G. Yamaguti-Hayakawa1, M. Ozelo1

Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley